Amylin Pharmaceuticals Inc. named Orville G. Koltermanmedical director. He was program director of the GeneralClinical Research Center and medical director of the DiabetesCenter, both at the University of California, San Diego MedicalCenter. Christopher Moyses was named senior director ofclinical development, Europe. He was cardiovascular drug teamleader at ICI Pharmaceuticals Inc. Dennis Mulvey was namedsenior director of process development. He was manager ofpeptide manufacturing at ProCyte Corp. John L. Tedesco wasappointed director of quality control. He was director ofmanufacturing operations at Somatogen Inc. And Laurie Peltierwas named director of project management. She was director ofdevelopment at Quintiles Inc. Amylin (NASDAQ:AMLN) isfocused on the development of amylin-based products.
W. Barry McDonald was named senior vice president ofmarketing and business development at Hycor Biomedical Inc.of Garden Grove, Calif. He was president and chief executiveofficer of Photest Diagnostics Inc. Hycor (NASDAQ:HYBD)specializes in medical and diagnostic products.
Cygnus Therapeutic Systems of Redwood City, Calif., has namedAlan F. Russell vice president of scientific affairs. Russell wasvice president for scientific affairs at Chiron Corp. Cygnus(NASDAQ:CYGN) develops transdermal drug delivery systems.
Noel Buskard was named medical director of Quadra LogicTechnologies Inc. He is a former medical adviser to the surgeongeneral of Canada. The Vancouver, British Columbia, company(NASDAQ:QLTIF) is developing photosensitive drugs.
Allelix Biopharmaceuticals Inc. has named David Bichandirector of regulatory and clinical affairs. He was director ofmedical affairs at Ortho-McNeil Inc. Allelix (TSE:AXB) ofToronto focuses on products for tissue repair andimmunological and inflammatory diseases.
Synergen Inc. (NASDAQ:SYGN) has appointed Christine C.Booker director of quality assurance. Booker was manager ofquality at Genentech Inc.
(c) 1997 American Health Consultants. All rights reserved.